WO2006061207A1 - Capteur de detection d'hydrates de carbone - Google Patents

Capteur de detection d'hydrates de carbone Download PDF

Info

Publication number
WO2006061207A1
WO2006061207A1 PCT/EP2005/013114 EP2005013114W WO2006061207A1 WO 2006061207 A1 WO2006061207 A1 WO 2006061207A1 EP 2005013114 W EP2005013114 W EP 2005013114W WO 2006061207 A1 WO2006061207 A1 WO 2006061207A1
Authority
WO
WIPO (PCT)
Prior art keywords
sensor
carbohydrate
analyte
lectin
glucose
Prior art date
Application number
PCT/EP2005/013114
Other languages
English (en)
Inventor
Jesper Svenning Kristensen
Klaus Gregorius
Casper Struve
John Myhre Frederiksen
Yihua Yu
Original Assignee
Precisense A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Precisense A/S filed Critical Precisense A/S
Priority to DK05817676.9T priority Critical patent/DK1828773T3/da
Priority to AT05817676T priority patent/ATE514084T1/de
Priority to EP05817676A priority patent/EP1828773B1/fr
Priority to US11/791,924 priority patent/US8700113B2/en
Priority to CN200580046306.XA priority patent/CN101107524B/zh
Priority to JP2007543804A priority patent/JP4809363B2/ja
Priority to AU2005313564A priority patent/AU2005313564B2/en
Priority to CA2589547A priority patent/CA2589547C/fr
Priority to GBGB0611773.3A priority patent/GB0611773D0/en
Publication of WO2006061207A1 publication Critical patent/WO2006061207A1/fr
Priority to US12/085,961 priority patent/US8691517B2/en
Priority to DK06829339.8T priority patent/DK1955072T3/da
Priority to NZ568486A priority patent/NZ568486A/en
Priority to PCT/EP2006/011708 priority patent/WO2007065653A1/fr
Priority to AU2006322176A priority patent/AU2006322176B2/en
Priority to JP2008543719A priority patent/JP5033810B2/ja
Priority to EP06829339A priority patent/EP1955072B1/fr
Priority to CN200680045824.4A priority patent/CN101365947B/zh
Priority to AT06829339T priority patent/ATE514085T1/de
Priority to CA2631807A priority patent/CA2631807C/fr
Priority to NO20073392A priority patent/NO342192B1/no
Priority to NO20082858A priority patent/NO20082858L/no
Priority to US14/178,756 priority patent/US20140200336A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G01N33/54373—Apparatus specially adapted for solid-phase testing involving physiochemical end-point determination, e.g. wave-guides, FETS, gratings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose

Definitions

  • the present invention relates to a sensor, to a method of preparing the sensor and to a method of using the sensor.
  • the sensor may be used in the measurement or monitoring of carbohydrate in fluid, for example glucose in body fluid, using optical techniques.
  • the sensor is particularly suitable for use in situations in which glucose levels must be closely monitored and/or where glucose measurements must be taken repeatedly, such as in diabetes management.
  • a method of assaying a competitive binding is to use a proximity-based signal generating/modulating moiety pair (discussed in US 6232120) , which is typically an energy transfer donor-acceptor pair (comprising an energy donor moiety and an energy acceptor moiety) .
  • the energy donor moiety is photoluminescent (usually fluorescent) .
  • an energy transfer donor-acceptor pair is brought into contact with the sample (such as subcutaneous fluid) to be analyzed.
  • the sample is then illuminated and the resultant emission detected.
  • energy donor moiety or the energy acceptor moiety of the donor-acceptor pair is bound to a receptor carrier, while the other part of the donor-acceptor pair (bound to a ligand carrier) and any analyte present compete for binding sites on the receptor carrier.
  • Energy transfer occurs between the donors and the acceptors when they are brought together, which produces a detectable lifetime change (reduction) of the fluorescence of the energy donor moiety. Also, a proportion of the fluorescent signal emitted by the energy donor moiety is quenched.
  • the lifetime change is reduced or even eliminated by the competitive binding of the analyte.
  • the apparent luminescence lifetime for example, by phase- modulation fluorometry or time-resolved fluorometry (see Lakowicz, Principles of Fluorescence Spectroscopy, Plenum
  • the amount of analyte in the sample can be determined. .
  • the efficiency of the energy transfer depends on the quantum yield of the donor, the overlapping of the emission spectrum of the donor with the absorption spectrum of the acceptor, and the relative distance and orientation between the donor and the acceptor.
  • EP0561653 a method of interrogating a receptor and a ligand as described above, is disclosed.
  • An example of donor-acceptor energy transfer is fluorescence resonance energy transfer (Foerster resonance energy transfer, FRET) , which is non-radiative transfer of the excited-state energy from the initially excited donor (D) to an acceptor (A) .
  • FRET fluorescence resonance energy transfer
  • the donor typically emits at shorter wavelengths, and its emission spectrum overlaps with the absorption spectrum of the acceptor. Energy transfer occurs without the appearance of a photon and is the result of P10632WO 07.12.05
  • RET resonance energy transfer
  • FRET fluorescence resonance spectroscopy
  • an analyte-binding moiety with a donor (D) and an analyte analogue with an acceptor (A) , or vice versa, would create an assay capable of generating a measurable response based on the donor-to-acceptor distance.
  • binding of the D-"analyte-binding moiety" to A-"analyte analogue results in a decrease in donor intensity or lifetime.
  • the analyte in the sample competes for the analyte-binding moieties on D-"analyte-binding moiety", releasing D-"analyte-binding moiety" from the acceptor (A) .
  • the intensity decay time and phase angles of the donor are thus expected to increase with increasing glucose concentration.
  • WO91/09312 describes a subcutaneous method and device that employs an affinity assay based on glucose
  • glucose sensing by energy transfer which produce an optical signal that can be read remotely.
  • the acceptor could be a fluorophore. Any fluorescent signal 5 emitted by the energy acceptor moiety following excitation with a beam of incident radiation at a wavelength within the absorption spectrum of the energy acceptor moiety is unaffected by the FRET process. It is therefore possible to use the intensity of the fluorescent signal emitted by the
  • the energy acceptor moiety may, however, be a non- fluorescent dye. In this case a compound with fluorescence
  • Concanavalin A is a lectin.
  • the term "lectin" includes any carbohydrate-binding
  • Lectins show selective binding to carbohydrates via carbohydrate recognition domains (CRDs) . Lectins occur naturally in both monomeric and ⁇ iultimeric
  • Concanavalin A is not stable for long periods under assay conditions. Experiments by the inventors (see Example 8) suggest that Concanavalin A is stable at body temperature for less than 20 days. Also, Concanavalin A is toxic and potentially immunogenic (however, it is used in glucose assays in small quantities which are thought to be safe in the human body) .
  • sweet pea and lentil lectins could be used as glucose binding moieties in such systems ( tt A Potentially Implantable Fluorescent Glucose Sensor Based on Molecular Recognition in Poly(ethylene glycol) Hydrogels", Ryan J. Russell et al . , presented to American Institute of Chemical Engineers) .
  • these lectins are expected to have similar disadvantages to Con A.
  • US 6232130 discloses an assay in which low valency lectins ("carbohydrate binding ligands”) are used. These have 3 or fewer CRDs.
  • the assay uses an analyte analogue. ( "glycoconjugate” ) comprising a carbohydrate, a label (e.g. a FRET component) and a carrier molecule.
  • the carrier molecule may be a protein (e.g. bovine serum albumin, BSA) or a synthetic polymer.
  • the present inventors have appreciated that there is a need to find carbohydrate binding moieties which have good stability and which do not have the disadvantages associated with Con A. They have investigated the use of alternative carbohydrate binding moieties. Surprisingly, they have found that animal lectins, including human lectins, can be used as carbohydrate binding moieties .
  • the present invention provides a sensor for the detection or measurement of carbohydrate analyte in fluid, the sensor comprising components of a competitive binding assay the readout of P10632WO 07.12.05
  • the assay components comprising: an animal lectin,- and an analyte analogue capable of competing with carbohydrate for binding to the lectin.
  • the analyte is a monosaccharide.
  • the analyte is glucose.
  • the senor is suitable for the detection or measurement of glucose in body fluid, for example subcutaneous fluid. It is desirable for the sensor to be suitable for use in vivo, and this is discussed in more detail below.
  • the analyte analogue is capable of competing with glucose at physiological calcium concentrations.
  • Typical physiological calcium concentrations are in the range of 1.15 to 1.29 ⁇ iM.
  • Detection Suitable detection techniques include FRET, fluorescence energy transfer, fluorescence polarisation, fluorescence quenching, phosphorescence, luminescence enhancement, luminescence quenching, diffraction or plasmon resonance.
  • the binding assay generating the optical signal should preferably be reversible such that a continuous monitoring of fluctuating levels of analyte can be achieved. This reversibility is a particular advantage of the use of a binding assay format in which the components of the assay are not consumed.
  • the detectable or measurable optical signal is generated using a proximity based signal P10632WO 07.12.05
  • a signal is generated or modulated when a first member of the pair is brought into close proximity with a second member of the pair.
  • the proximity based signal generating/modulating moiety pair is an energy donor moiety and energy acceptor moiety pair.
  • Energy donor moieties and energy acceptor moieties are also referred to as donor and acceptor chromophores respectively.
  • An energy acceptor which does not emit fluorescence is referred to as a quenching moiety.
  • the lectin is labelled with one of an energy donor and energy acceptor moiety pair and the analyte analogue is labelled with the other of the energy donor and energy acceptor moiety pair.
  • the most preferred embodiment of the sensor of the invention incorporates an assay which generates an optical readout using the technique of FRET.
  • the assay is to be used in vivo, it is desirable for donors to fluoresce at 550 to around 700 nm and for acceptors to absorb light at around 650 nm. This avoids overlap between the donor fluorescence and in vivo autofluorescence at lower wavelengths.
  • Alexa Fluor 594TM e.g. as succinimidyl ester
  • This dye absorbs at 594 nm and fluoresces at 620 nm.
  • HMCV dyes described in WO05/059037 are suitable energy acceptor moieties for use in the invention. These dyes are stabilised carbenium ions.
  • An example is Hexa- Methoxy-Crystal Violet succinimidyl ester (HMCV-I) . P10632WO 07.12.05
  • QSY 21TM may be used as an energy acceptor moiety with Alexa Fluor 594TM as an energy donor moiety.
  • Fluorescence lifetime or fluorescence intensity measurements may be made. Fluorescence lifetime may be measured by phase modulation techniques (discussed below) .
  • the lectin is labelled with AlexaFluor 594 as energy donor moiety
  • the analyte analogue is labelled with HMCV-I as energy acceptor moiety
  • fluorescence lifetime is measured by phase modulation techniques .
  • the material retaining the assay components preferably provides sufficient space for the energy donor and the energy acceptor moieties to separate when not bound to one another so that energy transfer can cease.
  • the lectin provides a stable signal in the assay for at least 10 days, more preferably for at least 14 days. It is particularly preferable that a stable signal is provided when the sensor is implanted in the human body.
  • MBL was stable in a glucose assay for at least 17 days (see Example 8) .
  • Earlier accounts reported a biological half-life for MBL of 4-7 days (Kilpatrick (2002) Transfus. Med. 12, 335) .
  • the lectin is a C-type (calcium dependent) lectin.
  • the animal lectin is a vertebrate lectin, for example a mammalian lectin, more preferably a human or humanized lectin.
  • a vertebrate lectin for example a mammalian lectin, more preferably a human or humanized lectin.
  • it may alternatively be a bird lectin, fish lectin or an invertebrate lectin such as an insect lectin.
  • the lectin is a human lectin derived from the human body.
  • the lectin may be a recombinantly manufactured lectin.
  • the lectin may be a humanised animal lectin, for example a humanised bovine lectin. This applies where there is a corresponding human lectin.
  • the lectin may be humanised in an analogous way to antibodies.
  • the lectin is in multimeric form.
  • Multimeric lectins may be derived from the human or animal body.
  • the lectin may be in monomeric form.
  • Monomeric lectins may be formed by recombinant methods or by disrupting the binding between sub-units in a natural multimeric lectin derived from the human or animal body. Examples of this are described in US 6232130.
  • the lectin has three or more CRDs. More preferably, the lectin has 6 or more CRDs .
  • the lectin is a collectin (collagen-like lectin) .
  • These are C-type animal lectins which have collagen like sequences (Gly-Xaa-Yaa triplet) .
  • MBL is a C- type collectin whereas Concanavalin A is a C-type lectin.
  • Monomeric collectin CRDs can be prepared by the action of collagenase.
  • the lectin is mannose binding lectin, conglutinin or collectin-43 (e.g. bovine CL-43) (all serum collectins) or a pulmonary surfactant protein (lung collectins) .
  • Mannose binding lectin also called mannan binding lectin or mannan binding protein, MBL, MBP
  • MBL is a collagen-like defence molecule which comprises several
  • each sub-unit has a molecular weight of around 75 kDa, and can be optionally complexed with one or more MBL associated serine proteases (MASPs) .
  • MASPs MBL associated serine proteases
  • Each polypeptide contains a CRD.
  • each sub-unit presents three carbohydrate binding sites.
  • Trimeric MBL and tetrameric MBL (which are the major forms present in human serum, Mollet et al. , Journal of Immunology, 2005, page 2870-2877) present nine and twelve carbohydrate binding sites respectively.
  • MBL occurs naturally in the body as part of the innate immune system where it binds mannose moieties coating the surface of bacteria. Human MBL is not toxic and is non- immunogenic to humans .
  • MBL of other species is expected to be immunogenic but not toxic to humans.
  • Human MB-L is commercially available both in a form derived from the human body and in a recombinantly manufactured form. .It is used as a replacement therapy in the treatment of MBL deficient patients who are believed to have increased susceptibility to infectious diseases.
  • the lectin is MBL substantially in trimeric and/or tetrameric form. As explained above, trimeric MBL and tetrameric MBL are believed to be the major naturally occurring multimeric forms in human serum.
  • the lectin may be a pulmonary surfactant protein selected from SP-A and SP-D. These proteins are similar to MBL. They are water-soluble collectins which act as calcium dependent carbohydrate binding proteins in innate host-defence functions . SP-D also binds lipids . SP-A has a "bouquet” structure similar to that of MBL (Kilpatrick DC (2000) Handbook of Animal Lectins, p. 37) . SP-D has a tetrameric "X" structure with CRDs at each end of the W X" . P10632WO 07.12.05
  • animal lectins are set out in Appendices A, B and C of "Handbook of Animal Lectins: Properties and Biomedical Applications", David C. Kilpatrick, Wiley 2000.
  • the lectin is preferably labelled as discussed above. More preferably, the lectin is labelled with an energy donor moiety.
  • the analyte analogue comprises a plurality of carbohydrate or carbohydrate mimetic moieties which bind to binding sites of the lectin.
  • carbohydrate includes sugars.
  • Suitable carbohydrate mimetic moieties include peptides such as keratin peptide (SFGSGFGGGY) which mimics N-acetyl glucosamine. It has been shown that keratin peptide can P 10632WO 07.12.05
  • MBL Mantacto et al . 2001 J. Immunol. 166, 4148- 4153
  • an analyte analogue which does not bind all the , binding sites is more readily displaced by analyte, which ; binds all the binding sites, than an analyte analogue which does bind all the binding sites. This explains why an analyte analogue containing mannose, which has a higher affinity for MBL than does glucose, can be displaced by glucose.
  • the parameters which affect avidity of an analyte analogue for a given lectin are: number of carbohydrate or carbohydrate mimetic moieties; affinity of the carbohydrate or carbohydrate mimetic moieties for the lectin; calcium concentration (at least for MBL) ; and flexibility of the analyte analogue. Physiological calcium concentration cannot be controlled. However, the other parameters can be selected to give an analyte analogue with an appropriate measurement P10632WO 07.12.05
  • analyte analogues e.g. those of US 6232130
  • the carbohydrate and energy donor or energy acceptor moieties have fixed positions. This means that the analyte analogues cannot necessarily adopt a conformation which allows binding of a plurality of carbohydrate moieties to lectin CRDs.
  • the relative positioning of the carbohydrate and energy donor or energy acceptor moieties in such analyte analogues may not allow optimum interaction between the energy donor and acceptor moieties when the analyte analogue and lectin are bound. This will affect FRET and weaken the optical signal.
  • the assay is capable of measuring blood glucose for concentrations over at least part of the range of 0 to 35 mM glucose, for example over the range of 0 to 25 mM glucose.
  • the IC 50 value is around 15 mM glucose.
  • the assay is capable of measuring glucose concentrations over the range of 2 to 10 mM glucose. A dosage-response curve which is as close as possible to linear within this range is desirable.
  • the analyte analogue may be a carbohydrate-protein conjugate or a carbohydrate-dendrimer conjugate.
  • carbohydrate mimetic moieties may be used instead of or in addition to carbohydrate moieties.
  • suitable carbohydrates for use in such conjugates are monosaccharides and oligosaccharides.
  • Suitable monosaccharides are optionally derivatised tetroses, pentoses, hexoses, heptoses or higher homologous aldoses or ketoses, for example optionally derivatised D- glucose, D-mannose, N-acetyl-D-glucosamine, L-fucose, D- fructose, D-tagatose or D-sorbitol.
  • Suitable oligomers may be linear or branched homooligomers or mixed oligomers, for example containing from 2 to 50 carbohydrate units.
  • the preferred glycosylation is 1 ⁇ 6 or 1 ⁇ 2, as 1 ⁇ 3 and 1 ⁇ 4 glycosylation is expected to interrupt MBL binding.
  • nona(1 ⁇ 6) - ⁇ -glucose (dextran 1500 Da) is expected to have higher avidity for MBL than 1,3- ⁇ -D-glucoses (e.g. laminanarihexaose) .
  • Suitable oligosaccharides include pannose, maltose, maltotriose, isomaltotriose, D-leucrose, erlose, D-palatinose, D-turanose or 1 to 250 kDa dextran (preferably 1 to 40 kDa dextran, for example 1 kda, 1.5 kDa, 5 kDa, 6 kDa, 10 kDa, 12 kDa, 20 kDa, 25 kDa or 40 kDa dextran) .
  • the analyte analogue comprises at least one carbohydrate moiety selected from D-fructose, D-leucrose, N- acetyl-glucosamine, D-mannose, L-fucose, N-acetyl- P10632WO 07.12.05
  • the analyte analogue comprises at least one glucose moiety and/or at least one N-acetyl glucosamine moiety and/or at least one mannose moiety, since these have a high affinity for MBL and other animal lectins. It is believed that these moieties bind to binding sites of the lectin via their C3 and C4 hydroxyl groups ,
  • dendrimer "wedges” used to construct dendrimers (e.g. TRIS derived trisaccharide with an amine linker, shown below) .
  • Such “wedges” could be conjugated onto a protein such as HSA
  • Preferred proteins for use in the conjugate are human proteins having a molecular weight of at least 10 kDa, preferably at least 20 kDa.
  • the protein has a non-globular overall tertiary structure. It is believed that this assists binding at more than one binding site, leading to high avidity.
  • Monoclonal antibodies such as herceptin and RemicadeTM (an immunoglobulin having several globular domains with a non-globular "Y"-shaped overall tertiary structure) are suitable.
  • Other alternative suitable proteins are human thrombin, human lactoferrin and Factor XIII. P10632WO 07.12.05
  • the protein may be a lectin-derived protein, for example a lectin with the CRDs removed.
  • the conjugate may be a carbohydrate-albumin conjugate.
  • the conjugate may be a mannose-HSA conjugate or a mannose-BSA (bovine serum albumin) conjugate.
  • mannose-HSA conjugate or a mannose-BSA (bovine serum albumin) conjugate.
  • conjugates of this type are not preferred since, as mentioned above, binding to MBL has been found to be dependent on calcium concentration. At physiological calcium concentrations a 70 kDa mannose-HSA conjugate with 20 mannose residues was found not to bind MBL. The dependence on calcium concentration decreases with increasing mannosylation.
  • Man-ITC N-isothiocyanato-4- aminophenyl-O- ⁇ -D-mannopyranoside
  • Dendrimers for use in the invention preferably have amine-functionalised, carboxylic acid-functionalised or hydroxyl-functionalised surfaces.
  • the dendrimers are of the polyamidoamine (PAMAM) or polypropylenimine (DAB) type.
  • PAMAM polyamidoamine
  • DAB polypropylenimine
  • the molecular weight is less than 60 kDa, for example around 2 to 10 kDa.
  • Such dendrimers can be cleared by the kidney (Kobayashi et al., 2004, J. Mag. Reson. Imaging 20(3) 512-518) .
  • the analyte analogue may be an optionally derivatised polymer of carbohydrate and/or carbohydrate mimetic moieties (both included in the term "polysaccharide” used herein) .
  • Dextran a glucose polymer, poly(l ⁇ 6)- ⁇ - glucose
  • MBL MBL
  • similar lectins The P10632WO 07.12.05
  • a glucose assay based on dextran and MBL can optimally measure glucose concentrations of around 30 mM. This is much higher than the normal 5 mM glucose concentration in blood. Such an assay can measure glucose concentrations from 0 to 10 mM with a sensitivity of only about one third of the total phase response (0.25 2 Phase shift per mM GIc, see Example 7) .
  • the present inventors therefore looked for alternative analyte analogues which would bind MBL and similar lectins less strongly, so that more than one third of the total phase response would be available in the 0 to 10 mM glucose range.
  • dextran with periodate which oxidatively cleaves the glucose pyranose ⁇ ring between the 2 and 3 or 3 and 4 carbons to form a dialdehyde
  • periodate which oxidatively cleaves the glucose pyranose ⁇ ring between the 2 and 3 or 3 and 4 carbons to form a dialdehyde
  • MBL binds to the 3 and 4 equatorial hydroxyls of glucose as explained above.
  • the 3 and 4 hydroxyl groups could inactivated in other ways (for example by oxidation, reduction, alkylation, substitution, glycosylation or esterification) .
  • periodate treated dextran-MBL binding is not prevented by physiological calcium concentrations. This is in contrast to mannose-HSA conjugate MBL binding as discussed above. It would have been expected that periodate-treated dextran MBL P10632WO 07.12.05
  • dialdehyde Treatment of the dialdehyde with ammonia or an amine followed by reduction (e.g. with sodium cyanoborohydride) can be used to give an aminated dextran.
  • a procedure can also be used in which the dialdehyde is aminated followed by optional catalytic hydrogenation to yield the free amine.
  • Benzylamine is a useful amine in this context as the intermediate before hydrogenation is a dextran derivative with lipophilic moieties.
  • a benzylamine derived aminated dextran can. be used to assess the degree of periodate cleavage using spectrophotometry techniques. If the benzyl group is removed by catalytic hydrogenation, energy donor or energy acceptor moieties can be coupled to the remaining amine.
  • a polysaccharide-based analyte analogue can be synthesised which bears different carbohydrate or carbohydrate mimetic moieties of different affinity for MBL and similar lectins.
  • Derivatisation of dextran with mannose moieties to adjust the glucose detection range in a Concanavalin A FRET assay is disclosed in Ballerstadt et al . , Diabetes Technology & Therapeutics, vol. 6, no. 2, 2004.
  • Galactose binds to MBL with very low affinity.
  • N-acetyl-glucosamine has a high affinity for MBL.
  • an analyte analogue containing N-acetyl- glucosamine moieties would have higher avidity for MBL than the underivatised analyte analogue.
  • the analyte analogue is selected from optionally derivatised dextran, mannan, amylose, amylopectin, glycogen, hyaluronate, chondroitin, heparin, dextrin, inulin, xylan, fructan and chitin.
  • galactose has very low affinity for MBL
  • a non-derivatised polymer of galactose such as agarose is not preferred as an analyte analogue.
  • the skilled person would be aware of ways in' which a polysaccharide can be derivatised with carbohydrate moieties.
  • amine-functionalised polysaccharides for example aminodextran, which is commercially available from CarboMer, San Diego, California, USA, Cat. No. 5-00060 or Molecular Probes, Eugene, Oregon, USA, Cat No. D1862
  • aminated dextrans referred to above may conveniently be derivatised.
  • alcohol groups in the polysaccharide and amine groups in the carbohydrate or carbohydrate mimetic moieties may be linked using divinylsulphone.
  • suitable carbohydrate moieties for derivatisation of polysaccharides are those set out in connection with carbohydrate-protein and carbohydrate- dendrimer conjugates above.
  • the analyte analogue may be a synthetic polymer.
  • Synthesis of an artificial polymer rather than derivatisation of a protein or polysaccharide allows the parameters of the polymer (for example molecular flexibility, water solubility, molecular weight, nature of carbohydrate or carbohydrate mimetic moieties, number of carbohydrate or carbohydrate mimetics moieties, number of proximity based signal generating/modulating moieties) to be readily controlled to improve assay performance.
  • a synthetic polymer has the advantage that the number of carbohydrate moieties can be controlled independently of the length of the polymer.
  • using non-ring containing monomers such as 2-hydroxyethyl acrylate (HEA) in the polymer gives increased molecular rotational flexibility compared with dextran.
  • HSA 2-hydroxyethyl acrylate
  • Globular ligands concentrate binding moieties and proximity based signal generating/modulating moieties on a spherical surface so that they are close.
  • dextran which is linear
  • the backbone consists of binding moieties, and consequently it is not possible to control whether binding is close to or remote from a proximity based signal generating/modulating moiety. This can be controlled in the synthetic polymer by positioning the binding moieties close to the proximity based signal generating/modulating moieties.
  • the analyte analogue is a non-saccharide flexible water-soluble polymer bearing pendant carbohydrate or carbohydrate mimetic moieties.
  • the term "flexible” includes polymers which are capable of significant intermonomeric rotation.
  • the polymers do not contain bulky groups (for example ring structures, tert-butyl groups or other sterically large groups) other than the pendant carbohydrate or carbohydrate mimetic moieties and proximity based signal generating/modulating moieties.
  • such polymers have very few double bonds in the backbone structure (for example less than 10 %) .
  • such polymers do not have a globular tertiary structure, although they may have such a structure.
  • the polymer is unbranched (unlike the dendrimers discussed above) .
  • This improves flexibility of the polymer.
  • the polymer may be branched or cross- linked to some extent provided that this does not lead to formation of a hydrogel.
  • 1 to 5 branchings in a polymer with an overall molecular weight of 100 kDa is . . acceptable.
  • water soluble includes polymers having a water solubility at room temperature of at least 4 mg/ml, preferably at least 25 mg/ml, more preferably at least 50 mg/ml, for example at least 100 mg/ml.
  • the solubility will be higher at body temperature. It is important that the polymer is water soluble so that it will dissolve in interstitial fluid when used in a sensor in the body as discussed below.
  • the polymer should be water soluble even when bound to a carbohydrate binding molecule such as MBL.
  • the polymer includes no more than 1 to 5 types of monomer unit, more preferably no more than 3 monomer units.
  • the polymer is a co-polymer comprising first monomer unit residues bearing pendant carbohydrate or P10632WO 07.12.05
  • carbohydrate mimetic moieties and second monomer unit residues bearing pendant proximity based signal generating/modulating moieties may be used.
  • a single monomer unit residue bearing both pendant carbohydrate or carbohydrate mimetic moieties and pendant proximity based signal generating/modulating moieties may be used.
  • the use of first and second monomer units is preferred, since the amounts of carbohydrate or carbohydrate mimetic moieties and proximity based signal generating/modulating moieties can then be controlled independently.
  • the co-polymer is a random co-polymer. However, it may also be an alternating co-polymer. Use of a block co-polymer with large blocks is not preferred. However, a block co-polymer with blocks of low molecular weight (for example 1 to 3 kDa) may be used.
  • the polymer when . used in an assay with MBL as a carbohydrate binding molecule, binds to MBL at 0 mM glucose at least -50 % as strongly as aminodextran, more preferably at least as strongly as aminodextran, but is more easily inhibited. It is particularly desirable that the polymer is easily inhibited (large proportion of total phase response) over the range of 0 to 35 mM glucose, and especially over the range of 2 to 15 mM. This provides an assay over glucose concentrations of particular physiological interest which is more sensitive than a similar assay using aminodextran as a glucose analogue.
  • More than one type of monomer unit residue bearing carbohydrate or carbohydrate mimetic moieties may be present.
  • the carbohydrate or carbohydrate mimetic moieties may be different, with different affinities for MBL and similar lectins. P10632WO 07.12.05
  • the first monomer units are each a double bond-containing derivative of a carbohydrate or carbohydrate mimetic moiety.
  • the first monomer units may each be a double bond-containing molecule containing a functional group to which the carbohydrate or carbohydrate mimetic moiety can be linked, suitably after polymerisation.
  • the double bond-containing derivative of the carbohydrate or carbohydrate mimetic moiety is an allyl or vinyl containing derivative of a carbohydrate or carbohydrate mimetic moiety.
  • suitable double bond- containing derivatives of carbohydrate or carbohydrate mimetic moieties include homologues of allyl derivatives, for example 3-butenyl or 4-pentenyl derivatives, or styrene derivatives with the carbohydrate or carbohydrate mimetic moiety at the 4 position.
  • Further suitable double bond- containing derivatives of carbohydrate or carbohydrate mimetic moieties include HEA, 2-hydroxyethyl methacrylate (HEMA) or vinyl alcohol (VA) based derivatives.
  • the carbohydrate or carbohydrate mimetic moieties may be linked to amine, acid, alcohol and/or sulphone functional groups of the first monomer units (or single monomer units).
  • alcohol groups in the monomer units and amine groups in the carbohydrate or carbohydrate mimetic moieties may be linked using divinylsulphone.
  • the linkage should not be via the C3-OH or C4-OH groups, since these are important in binding to MBL. In this case, divinylsulphone linkage may be inappropriate.
  • Amino derivatised carbohydrate moieties can be- produced by reductive amination of disaccharides. This allows the carbohydrate moiety to be linked at its anomeric position (Cl) .
  • the carbohydrate or carbohydrate mimetic moiety could be connected to alcohol groups (e.g. in HEA) by Fischer glycosidation.
  • first monomer units or single monomer units
  • Suitable carbohydrates for use in the copolymer are as discussed in connection with Carbohydrate- Protein Conjugates above.
  • the second monomer units are each a double bond-containing molecule containing a functional group to which the proximity based signal generating/modulating moiety can be linked, suitably after polymerisation.
  • Suitable functional groups include acid, alcohol and/or sulphone. Linkage after polymerization helps to minimize I ⁇ SS of the expensive proximity based signal generating/modulating moieties .
  • ⁇ units may contain the proximity based signal generating/modulating moieties.
  • suitable polymerisable groups and linkages applies.
  • the second monomer units are each N- (3-aminopropyl)methacrylamide or a derivative thereof.
  • the single monomer units are each a double bond containing, carbohydrate or carbohydrate mimetic moiety containing derivative of lysine. An example is shown below (multistep reaction scheme) : P10632WO 07.12.05
  • the starting material in this reaction scheme is methacryloyl-L-lysine, available through PolysSciences Europe (Eppelheim, Germany) .
  • the alpha amine group could be linked to the proximity based signal generating/modulating moiety.
  • the polymer further contains third monomer unit residues which do not bear pendant carbohydrate or carbohydrate mimetic or proximity based signal generating/modulating moieties . This helps to increase flexibility.
  • Flexibility is increased by using third monomer units which are sterically unhindered such as HEA. Flexibility is also increased by using third monomer units which are uncharged. A polymer containing no third monomer units would have a large number of positively charged ammonium groups which would need to be inactivated to minimize decreased flexibility because of electrostatic repulsion. More than one type of third monomer can be included in the polymer.
  • the third monomers units are each a double bond-containing molecule containing a hydrophilic group, for example a hydroxyl group. It is not preferred for the third monomers units to be a lipophilic double bond-containing molecule, for example styrene.
  • the third monomer units are each HEA, vinyl pyrrolidone, MMA, HEMA, vinyl alcohol and/or P10632WO 07.12.05
  • the monomer units are reacted by addition polymerization.
  • the addition polymerization may be free- radical initiated, for example using potassium peroxodisulfate (PPS) or another peroxide compound.
  • PPS potassium peroxodisulfate
  • condensation polymerization for example ionic condensation polymerization
  • ring opening polymerization for example atom transfer radical polymerization
  • ARP ARP
  • monomer units are mixed before initiator is added.
  • the polymerization reaction takes less than two days.
  • the length of the polymerization can be used to control the molecular- weight of the co-polymer product.
  • the polymerization reaction takes place under oxygen-free conditions .
  • the polymerization reaction is carried out at room temperature.
  • the first monomer units are preferably present in the reaction mixture in an amount of 20 to 70 wt%, more preferably in an amount of 30 to 50 wt%.
  • the third monomer units are preferably present in the reaction mixture in an amount of 5 to 15 wt%.
  • composition of the polymer does not exactly reflect the amounts of monomer P10632WO 07.12.05
  • the analyte analogue may consist of two or more separate entities which together act as an analyte analogue.
  • the analyte analogue may consist of a first entity with at least two analyte analogue moieties and a second entity which is an analyte binding molecule such as a lectin.
  • acceptor labelled MBL and donor labelled MBL can be used together with unlabelled dextran or unlabelled synthetic polymer as a template to bring the donor labelled MBL and acceptor labelled MBL in proximity of each other so that FRET occurs . (example using Con A given by Gestwicki et al. (2002) Chemistry and Biology 9, pl63) .
  • the analyte analogue is preferably labelled with one or more proximity based signal generating/modulating moieties as discussed above.
  • the analyte analogue comprises one or more energy acceptor moieties (for example HMCV-I or Alexa Fluor 594TM, discussed above) .
  • it may also comprise one or more energy donor moieties.
  • the proximity based signal generating/modulating moieties may be attached to the analyte analogue as discussed in connection with the carbohydrate or carbohydrate mimetic moieties above.
  • labelling of dextran can be achieved by direct divinylsulphone coupling or by amination (as described above) followed by coupling.
  • an amine derivatised dextran is used as the analyte analogue, care must be taken to avoid cross linking during attachment of the proximity based signal generating/modulating moieties, as this could lead to P 10632 WO 07.12.05
  • the analyte analogue should have a molecular weight high enough to prevent escape from the sensor but low enough that precipitation does not occur when the analyte analogue binds to the lectin.
  • Analyte analogues having a weight in the range of 25 to 250 kDa, more preferably 40 to 250 kDa, more preferably still 70 to 150 kDa, highly preferably 100 to 120 kDa, for example 110 kDa are preferred.
  • Analyte analogues based on 110 kDa dextran are particularly preferred.
  • analyte analogue and lectin are tethered together.
  • the components of the assay are retained by a material which has a pore size that permits diffusion of analyte. but not the assay components.
  • this selectivity may be achieved in other ways, for example by using a material which allows diffusion of uncharged materials .
  • the components of the assay are retained by a shell or matrix material.
  • the analyte analogue and/or lectin may be grafted onto this material. More preferably, the material is biodegradable as described in WO00/02048.
  • the senor may comprise small particles retained by a shell of biodegradable material as described in
  • the components of the assay are retained by a shell of biodegradable material encapsulating the assay components whilst allowing glucose P10632WO 07.12.05
  • the biodegradable material comprises a co-polymer having hydrophobic and hydrophilic units, as described in WO2005/110207.
  • One or more assay component chambers may be present within the shell.
  • the co-polymer is a random copolymer.
  • the co-polymer has a permeability of at least 5.0 x ICT 10 cm 2 /s.
  • permeability is used to refer to the overall permeability of analyte (glucose) through hydrated copolymer which can be measured experimentally.
  • the co-polymer degrades over a period of one week to one year, for example 30 days.
  • a typical polymer thickness of 5 ⁇ m this corresponds to a degradation rate of 0.17 ⁇ m/day.
  • the biodegradable material has a molecular weight cut-off limit of no more than 25000 Da.- More preferably, the biodegradable material has a molecular weight cut-off limit of no more than 1000-0 Da.
  • the weight fraction of the hydrophobic units is from 10 to 90 % of the co-polymer, more preferably from 10 to 50 % of the co-polymer.
  • the molecular weight of each hydrophilic unit is from 200 to 10000 Da, more preferably from 400 to 4000 Da.
  • the hydrophilic units of the co-polymer each comprise an ester of polyethylene glycol and a diacid.
  • polyethylene glycol a mixed polymer of ethylene glycol and propylene glycol may be used, and/or the polyether backbone may be substituted with hydrophobic and/or hydrophilic groups.
  • P10632WO 07.12.05 a mixed polymer of ethylene glycol and propylene glycol may be used, and/or the polyether backbone may be substituted with hydrophobic and/or hydrophilic groups.
  • polyethylene glycol poly-tetrahydrofuran
  • poly-THF poly-tetrahydrofuran
  • the hydrophilic units comprise terephthalic acid and/or succinic acid as diacids .
  • suitable diacids are oxalic acid, tartaric acid, phthalic acid, aspartic acid, malonic acid and oligomeric or polymeric diacids, for example poly(dimer acid-sebacic acid) .
  • the diacid is terephthalic acid only.
  • the molar ratio of terephthalic acid to succinic acid is 1:2 to 2:1, suitably 1:1.
  • the hydrophilic units of the co-polymer may comprise oligomers.
  • Suitable oligomers are oligomers of hydroxyethylmethacrylate (HEMA) , vinylpyrrolidone, vinyl alcohol, carbohydrates, ethylene oxide and/or 2-acrylamido- 2-methyl propane sulfonic acid.
  • HEMA hydroxyethylmethacrylate
  • biodegradable linkages for example ester linkages such as terephthalate linkages
  • the molecular weight of each hydrophobic unit is from 400 to 5000 Da.
  • the hydrophobic units of the co-polymer comprise an ester of butane-1, 4-diol and a diacid.
  • butane-1, 4-diol, pentane-1, 5-diol or hexane- 1,6-diol may be used.
  • the hydrophobic units comprise terephthalic acid and/or succinic acid as diacids.
  • the molar ratio of terephthalic acid to succinic acid is 1:2 to 2:1, suitably 1:1.
  • the hydrophobic units comprise terephthalic acid only as diacid. Other suitable diacids are given above. P 10632WO 07.12.05
  • the hydrophobic units of the co-polymer can comprise oligomers of methylmethacrylate (MMA) , polyurethane and/or amides (for example Nylon-6, oligo-N- tertiary butylacrylamide or oligo-N-isopropylacrylamide) .
  • MMA methylmethacrylate
  • polyurethane and/or amides for example Nylon-6, oligo-N- tertiary butylacrylamide or oligo-N-isopropylacrylamide
  • biodegradable linkages for example ester linkages such as terephthalate linkages
  • Preferred polymers have the general formula aPEG(T/S)bPB(T/S) c where "a” denotes the molecular weight of the PEG chain, "b” the weight fraction of the PEG(T/S) (polyethylene glycol terephthalate/succinylate) in the resulting polymer and "c” the weight fraction of the PB(T/S) (polybutylene terephthalate/succinylate) in the resulting polymer.
  • polymers examples include 600PEGT80PBT20, 1000PEGT80PBT20, 2000PEGT80PBT20, 4000PEGT80PBT20, 1000PEGT50PBT50 and 1000PEG(T/S) 60PB(T/S)40 (T/S 50%) .
  • the polymers are biodegradable, have high glucose permeability and have molecular weight cut-off properties at around 25000 Da.
  • the envelope of co-polymer preferably has a thickness of 1 to 50 ⁇ m .
  • the present invention relates to a method of preparing a sensor as described herein .
  • Chemical methods for the preparation of polymer microcapsules include phase separation ( coacervation) , solvent evaporation and/or extraction .
  • Suitable physical methods for the preparation of polymer microcapsules include spray drying, spray coating, spray chilling, rotary disk atomisation, fluid bed coating, P 10632WO 07.12.05
  • coextrusion for example stationary nozzle coextrusion, centrifugal head coextrusion, or submerged nozzle coextrusion
  • pan coating for example stationary nozzle coextrusion, centrifugal head coextrusion, or submerged nozzle coextrusion
  • the present invention relates to a method of detecting glucose using a sensor as described herein, comprising implantation of the sensor into the skin of a mammmal, detection or measurement of glucose using external optical means .
  • the present invention relates to a method of detecting glucose using a sensor as claimed described above, comprising detection or measurement of glucose using external optical means by illumination of a said sensor present in or below the skin of a mammal.
  • the method further comprises degradation of biodegradable material in the sensor.
  • the sensor may be introduced within the skin by injection, preferably using a syringe, or by other methods, in particular by any method described in WO00/02048.
  • the sensor is preferably of a size suitable for injection through a narrow gauge needle to minimise the discomfort to the patient.
  • the sensor has a maximum dimension of 20 ⁇ m to 1 mm.
  • a rod-shaped sensor having a larger maximum dimension may be used.
  • the sensor may be introduced within the thickness of the dermis, or subdermally, or may be introduced to the epidermis, although in the latter case it would be likely to be expelled from the skin by outgrowth of the epidermal layers, possibly before the biodegradable material has degraded.
  • an optical signal generated in the sensor is preferably detected transcutaneously (i.e. through the higher layer(s) of the skin) thus obviating the need for any direct connection between the sensor and the external environment which may lead to infection.
  • detection may alternatively take place via a hollow or transparent means (for example a needle or optical fibre) which allows the sensor to be illuminated by external optical means without passing light through the skin.
  • a hollow or transparent means for example a needle or optical fibre
  • glucose measurements can be taken as often as is necessary with no adverse effects . This is a particular advantage in relation to the long-term care of diabetic patients because if glucose measurements are taken more frequently, tighter control can be maintained over the level of glucose in the blood and the risk of developing conditions related to poorly regulated blood glucose, such as retinopathy, nephropathy, neuropathy, general micro- and macrovascular damage and poor circulation, will be reduced.
  • the senor of the invention does not itself contain any of the optical components required to interrogate the readout of the assay (these being preferably provided separately and located outside the body) the sensor can easily be provided in a form which is injectable with minimal discomfort to the patient.
  • Sensors incorporating an assay employing the technique of FRET may be interrogated by supplying incident radiation at a wavelength within the absorption spectrum of the energy donor moiety and measuring the intensity of the emitted fluorescence or the lifetime of the excited state.
  • Commonly known methods are: P10632WO 07.12.05
  • Time-domain lifetime measurement a. Single photon counting b. Streak camera c. Gated detection (pulse sampling) d. Up-conversion 3. Frequency domain lifetime measurement a. Phase-modulation fluorometry (heterodyne detection) b. Phase sensitive detection (homodyne detection)
  • the preferred method for interrogating the assay is phase-modulation fluorometry.
  • a suitable optical set-up for interrogating the assay (Fig. 6) consists of a light-emitting diode (LED) 11, which emits light within the emission spectrum of the energy donor moiety.
  • the LED is operated by a driver circuit 13, which modulates the LED at a frequency which results in a sufficient phase shift, preferably in the range of 45°. For a fluorophore with a lifetime of 3 ns, the preferred frequency is 50 MHz.
  • the light emitted by the LED is filtered by an excitation filter 15 and directed towards the sensor 16 by a dichroic beam splitter 17 and focused onto the sensor/skin above the injected sensor 16 by a lens 19. The fluorescence emitted by the sensor is collected by the lens 19.
  • the light passes through the dichroic beam splitter and is filtered through an emission filter 21.
  • the filtered light is focused by a lens 23 onto the detector 25, in this case an avalanche photodiode (APD) .
  • the APD is reverse biased by an APD bias supply 27, which is controlled by a P10632WO 07.12.05
  • the signal from the APD is amplified by a trans-impedance amplifier 31, filtered by a bandpass filter 33 and sampled by a first analog-to- digital converter (ADC) 35.
  • ADC analog-to- digital converter
  • the modulated drive signal to the LED is sampled by a second ADC 37.
  • the signal sampled on the first ADC 35 is:
  • a 1 is the amplitude of the detected signal from the assay, f is the modulation frequency, (pa is the phase lag introduced by the donor fluorophore and ⁇ i is a fixed phase lag introduced by the electronic and optical set-up.
  • the signal sampled on the second ADC 37 is:
  • a 2 is the amplitude of the modulated drive signal to the LED and ⁇ 2 is a fixed phase lag introduced by the electronic set-up
  • the signal processing and control unit derives the phase lag ⁇ f i introduced by the energy donor moiety by comparing the two sampled signals and compensating for the fixed and known phase lags introduced by the electronics and optics. Measurements are taken by holding the fluorometer close to the skin and in alignment with the sensor.
  • the optical means should supply a first beam of incident radiation at a wavelength within the absorption spectrum of the energy donor moiety and preferably a second beam of incident radiation at a wavelength within the absorption spectrum of the energy acceptor moiety (this applies where the energy acceptor moiety is also a fluorophore) .
  • the optical means should preferably be capable of measuring optical signals generated in the sensor at two different wavelengths; wavelength 1 within the emission spectrum of the energy donor moiety (the signal generated in connection with the measurement of analyte) and wavelength 2 in the emission spectrum of the energy acceptor moiety (which could be the analyte signal or the internal reference or calibration signal) .
  • the fluorometer separately measures the following parameters:
  • the final output from the optical means e.g. the fluorometer
  • Equation 1 The final output from the optical means (e.g. the fluorometer) as given by Equation 1 above is converted to analyte concentration preferably by means of a computer using calibration data which can be obtained based on the principles set out in WO00/02048.
  • the present invention relates to a sensor for the detection or measurement of carbohydrate analyte in fluid, the sensor comprising components of a competitive binding assay the readout of which is a detectable or measurable optical signal retained by a P10632WO 07.12.05
  • the assay components comprising: a lectin; and an analyte analogue comprising optionally derivatised dextran in which the 3- and/or 4- hydroxyl groups of at least one of the glucose units have been inactivated, the analyte analogue being capable of competing with analyte for binding to the lectin.
  • the dextran is periodate-treated dextran.
  • the present invention relates to a sensor for the detection or measurement of carbohydrate analyte in fluid, the sensor comprising components of a competitive binding assay the readout of which is a detectable or measurable optical signal retained by a material that permits diffusion of analyte but not the assay components, the assay components comprising: a lectin; and an analyte analogue comprising a mannose-protein conjugate capable of competing with analyte for binding to the lectin.
  • the mannose-protein conjugate is one prepared using a molar ratio of mannose to HSA in the range of 10:1 to 150:1, for example 15:1, 30:1, 60:1 or 120:1.
  • the invention relates to a sensor for the detection or measurement of a carbohydrate analyte in fluid, the sensor comprising components of a competitive binding assay the readout of which is a detectable or measurable optical signal retained by a material that permits diffusion of the analyte but not the assay components, the assay components comprising: P10632WO 07.12.05
  • carbohydrate binding molecule labelled with one of a proximity based signal generating/modulating moiety pair; and a carbohydrate analogue capable of competing with the analyte for binding to the carbohydrate binding molecule, the carbohydrate analogue being a flexible water-soluble polymer comprising: polymerized residues of first monomer units, the first monomer unit residues bearing pendant carbohydrate or carbohydrate mimetic moieties and pendant moieties which are the other of the proximity based signal generating/modulating moiety pair; and/or
  • co-polymerised residues of second monomer units and third monomer units the second monomer unit residues bearing pendant carbohydrate or carbohydrate mimetic moieties and the third monomer unit residues bearing pendant moieties which are the other of the proximity based signal generating/modulating moiety pair.
  • the invention relates to a method of producing a polymer as described above, comprising one of the following procedures: a) polymerising monomer units each bearing a pendant carbohydrate or carbohydrate mimetic moiety and a pendant proximity based signal generating/modulating moiety and optionally third monomer units; b) co-polymerising first monomer units each bearing a pendant carbohydrate or carbohydrate mimetic moiety and second monomer units each bearing a pendant proximity based signal generating/modulating moiety and optionally third monomer units; WO 07.12.05
  • Fig. 1 shows the glucose dose response from a human MBL and dextran assay system for various dextran molecular weights (Example 6) .
  • Fig. 2 shows the glucose dose response from (a) a human MBL and 110 kDa dextran assay system and (b) a Con A and 110 kDa dextran assay system (Example 8) .
  • Fig. 3 shows the glucose dose response from a human MBL and HSA mannose ELLA assay system (Example 11) ;
  • Fig. 4 shows the glucose dose response from a human MBL and periodate-treated dextran ELLA assay system (Example 11) ;
  • Fig. 5 shows the glucose dose response from a human MBL and 70 kDa dextran assay system (Example 15) .
  • Fig. 6 shows a suitable optical set-up for interrogating the assay.
  • p-Aminophenyl- ⁇ -D-mannopyranosyl isothiocyanate Bovine serum albumin- ⁇ -D-mannopyranosyl isothiocyanate (23 eq Man pr. BSA), Human serum albumin, sodium periodate, Biotin-iV- hydroxy succinimide, o-phenylene dihydrochloride, benzylamine, ammonia, sodium cyanoborohydride (Sigma-Aldrich) .
  • Mannan binding lectin available from several sources e.g. Statens Serum Institute, Copenhagen, Denmark) .
  • Dialysis tube Spectra/Por (Spectrum Laboratories Inc., California, USA) .
  • Float-A-LyzerTM 25.000 MWCO dialysis tubing was from Spectrum Laboratories Europe (Breda, The Netherlands) .
  • Sorbitan monooleate (Span® 80), Azodiisobutyrodinitrile (AIBN) and 2-hydroxyethylacrylate were from Sigma-Aldrich.
  • N- (3-aminopropyl) methacrylamide hydrochloride was from PolysSciences Europe (Eppelheim, Germany) .
  • 2, 2 ' -Azobis [2- (2- imidazolin-2-yl)propane] dihydrochloride (VA-044) was from Wako GmbH (Neuss, Germany) .
  • AlIyI ⁇ -D-Glucopyranoside and AlIyI 2-acetamido-2-deoxy- ⁇ D-glucopyranoside were from Glycon Biochemicals, Germany.
  • AlIyI ⁇ -D-Galactopyranoside was from Sigma-Aldrich.
  • PBS is 20 mM Phosphate, 150 mM NaCl, pH 7.4, and TBS is 20 itiM TRIS, 150 mM NaCl, 1,25 mM CaCl 2 , pH 7.4 unless otherwise stated.
  • MBL Mannan Binding Lectin
  • PBS Phosphate buffered saline
  • TBS TRIS buffered saline
  • ELLA Enzyme Linked Lectin Assay.
  • Human MBL was buffer changed (by dialysis) to a 10 mM NaHCO 3 buffer containing 150 mM NaCl and 1.25 mM Ca 2+ , pH 8.7.
  • the dye used for staining was Alexa FluorTM 594 succinimidyl ester (AF594-SE) (Molecular Probes, Eugene, Oregon, USA) .
  • the dye was dissolved in dry DMSO and added slowly (10 min. ) to the MBL in bicarbonate buffer. Reaction was allowed to take place for 1 hour.
  • the staining was performed with 15 times molar excess (with respect to the polypeptide unit) of dye.
  • HMCV-I (Cl " ): TSTU (2-succinimido-l, 1, 3 , 3- tetramethyluronium tetrafluoroborate; 0.8 g, 2.6 mmol) was added to a solution of 4a (0.9 g, 1.26 mmol) and diisopropylethylamine (0.55 g, 4.5 mmol) in acetonitrile (15 mL) . The reaction mixture was stirred in a closed flask for 2 h, before it was poured into an ice-cold nearly sat. NaCl solution (approx. 150 mL) acidified with HCl-aq (4 mL, 2 M) .
  • 70 kDa aminodextran (0.5 mmol NH 2 /g dextran, i.e. 35 moles amine per mole dextran) prepared by an analogous method to that of Example 2 was stained in 10 mM NaHCO 3 pH 8.5, 150 mM NaCl with HMCV-I (Example 3) .
  • the dye was dissolved in dry DMSO and added slowly (10 min. ) to the dextran in bicarbonate buffer. Reaction was allowed to take place for 1 hour. The staining was performed with 8 times molar excess of dye. Purification was carried out by dialysis against 10 mM Tris buffer pH 7.4, 150 mM NaCl, 1.25 mM Ca 2+ , 2 mM NaN 3 .
  • the obtained degree of labelling of the stained dextran was determined by UV spectroscopy as 7.0 dyes per dextran.
  • AF594 stained human MBL (Example 1) and HMCVl-Dextran (Example 4) were mixed in TBS buffer (same as above) to concentrations of 10 ⁇ M of both components (using concentration of MBL-AF594 carbohydrate recognition domains, CRD, each with an Mw of approx 25kDa) .
  • the assay chemistry mixture was sucked into a hollow fibre (regenerated cellulose, diameter 0.2 mm) .
  • Fluorescence lifetime measurements were performed in a KOALA automated sample compartment (ISS,
  • the measured phase was an average of at least forty phase- angle recordings.
  • the fluorescence cell was emptied using a pipette, and refilled with buffer containing the next concentration of glucose. A delay of 20 minutes between measurements was introduced to allow the assay chemistry to reach equilibrium.
  • phase-angle at 500 mM glucose the fibre was washed several times with 10 mM TRIS buffer over a time period of 60 minutes. At this point the same phase-angle was obtained as for 0 mM Glucose. This demonstrates the reversibility of the assay.
  • Table 1 Absolute phase shifts for AF594-MBL and HMCVl-Dex70.
  • the PMT counts reflect the intensity increase of the system.
  • Example 5 was repeated using HMCVl-Dextran of molecular weight ranging from 20 kDa to 250 kDa (prepared in an analogous way to the HMCVl-Dextran used in Example 5) . It was found that the highest phase shift was achieved using 110 kDa HMCVl-dextran. The results are shown in Fig. 1.
  • Example 5 was repeated using a range of ratios of stained MBL:HMCVl-Dextran. It was discovered that a 1:4 ratio of stained MBL:HMCVl-Dextran (5 ⁇ M concentration of MBL-AF594 carbohydrate recognition domains, CRD, each with an Mw of P10632WO 07.12.05
  • Example 5 was repeated using MBL-AF594 and ConA-AF594 as lectin with 110 kDa HMCVl-dextran as analyte analogue in physiological TRIS buffer (pH 7.4, sodium, potassium and calcium present in physiological concentrations) .
  • the glucose concentration was varied between 2.5, 5 inM, 25 mM and 50 mM in cycles over 12 days . Measurements were taken at 5 minute intervals using a miniaturized time resolved fluorimeter.
  • MBL-AF594 the phase measurements at each glucose level were constant over time. A significant drift was observed in the experiment with Con A, resulting in a more than 10% reduction in the measured phase after 20 days. The results are shown in Fig. 2.
  • 70 kDa dextran (200 mg, 0.00286 ⁇ raiol) was dissolved in water (2.8 mL) and added to a 100 mM solution of sodium periodate in water (2.8 mL, 100 times molar excess) . The mixture was stirred in the dark for 1 h at room temperature. The resulting mixture was transferred to a dialysis tube (MWCO 10-12 k) and dialysed over night against 5 L water.
  • MWCO 10-12 k dialysis tube
  • the volume was adjusted to 8 ml.
  • the periodate-oxidised dextran was split into two aliquots (4 mL, 100 mg each) and treated for a half hour with 28 % aqueous ammonia (200 ⁇ L) and benzylamine (300 ⁇ L) respectively.
  • the imine and iminium derivates were then reduced with sodium cyanoborohydride (45 mg) overnight at room temperature, and pH around 10.
  • the reaction mixture was dialyzed against 2 x 1 L 20 mM TBS the following day.
  • the degree of amine incorporation in the periodate oxidised dextran was determined using elemental analysis.
  • Man-ITC (11.9 ing) was dissolved in DMSO (0.1 mL) and 20 mM Carbonate buffer (3.9 mL, pH 9.2) . An aliquot (1.6 mL) of this solution (corresponding to 120 times molar excess) was added to an Eppendorf vial containing HSA (0.4 mL) . The rest of the Man-ITC solution was diluted to double volume, and from the diluted volume, an aliquot (1.6 mL) was added to another eppendorf vial. This procedure was repeated until the four different HSA:Man-ITC mixtures had been prepared.
  • the four reaction mixtures were incubated in a shaker overnight at room temperature.
  • the resulting glycoconjugates were purified on a PD-10 column. During the purification, the buffer was changed to TBS. The degree of conjugation was determined using MALDI-TOF-MS.
  • Biotin-NHS (20 ⁇ l, 7 mg/ml in DMSO, -10-15 eq. per MBL monomer) was added to a solution of MBL (3 ml, 0.53 mg) in PBS (3 mL) . The solution was gently stirred for 2 h, then transferred to a dialysis tube (MWCO 10-12K) and dialysed against TBS (2 x 1 L) over the course of 24 h. The resulting biotinylated MBL (0.2 mg/ml) in TBS was used without further purification.
  • TBS buffer used in the ELLA assay is 20 mM TRIS, 150 inM NaCl, pH 7.4.
  • 20 mM CaCl 2 is used where antigen is HSA- mannose and 1.25 mM CaCl 2 (mimicking physiological calcium concentration) is used where antigen is aminated periodate- treated dextran.
  • a 96-well microtitre plate was coated, overnight at 5 0 C, with two columns of each of the antigens (HSA-Mannose from Example 10, aminodextran, benzylainino periodate-treated dextran from Example 9) (100 ⁇ L, 20 ⁇ g/mL) in TBS. Residual binding sites were blocked by the addition of 1 % (w/v) HSA in TBS (150 ⁇ L) . The wells were then washed (2 X 200 ⁇ L TBS) . Dilutions of glucose (from 100 mM to 0 mM) in biotinylated MBL prepared as described above (2 ⁇ g/mL) were added to a total volume of 100 ⁇ L.
  • a water-soluble 40 % Mannose copolymer was prepared by emulsion polymerisation as follows.
  • Span80 surfactant (5.7 g; HLB [hydrophile lipophile balance] 4.3, 10% w/w based on toluene)
  • AIBN (30 mg
  • toluene 57.3 g
  • the co-polymer (Example 12) (88.6 mg) was dissolved in 10 mM NaHCU 3 solution (3 ml; pH 8.5) .
  • the polymer solution was divided equally into three Eppendorf vials.
  • HMCV-I (Example 3) (19.6 mg; 26.1 ⁇ mol) was dissolved in dry DMSO (600 ⁇ l) .
  • the dye was added to the polymer solutions in 10 ⁇ l aliquots every 30 seconds, in such a manner that the first vial in total received 100 ⁇ l, the second vial received 200 ⁇ l and the third vial received 300 ⁇ l.
  • Assay chemistry including stained co-polymer solution (Example 13) (4 ⁇ L) and stained MBL solution (Example 1) (8.5 ⁇ L) in 10 mM TRIS buffer (12.5 ⁇ L) was mixed and P10632WO 07.12.05
  • the assay chemistry was then transferred to a fibre as in Example 5 with a syringe.
  • the fibre was mounted in a custom designed fibre-holder which fitted into a standard fluorescence cell (10 mm x 10 mm) .
  • Example 15 Sensor Formulation and Implantation
  • Fibres were made from 1000PEGT80PBT20 polymer (prepared as described in S. Fakirov and T. Gogeva, Macromol . Chem. 191 (1990) 603-614 with a target of 80 wt% hydrophilic segment and 20 wt% hydrophobic segment) by dipping a glass rod of diameter 700 ⁇ m into a 15% w/w solution of polymer in dichloromethane (DCM) and letting it dry at room temperature. This yielded hollow fibres of outer diameter 900 ⁇ m with a lumen of diameter 700 ⁇ m.
  • DCM dichloromethane
  • the fibre was filled with 5 ⁇ M with respect to CRD of AlexaFluor TM stained MBL (Example 1) and 20 ⁇ M of HMCV-I stained amino-dextran 150 kDa (prepared by an analogous method to that of Example 4) . Heating the polymer in order to melt it closed the fibre.
  • the welded fibre was tested for leakage before testing and insertion.
  • the glucose response measured by the use of time resolved fluorescence spectroscopy was as shown in Fig. 5.
  • This type of fibre can be placed in the top of the skin by the use of a needle.
  • a needle of suitable size (large enough to contain the wet fibre) is placed parallel to the skin surface at a depth of approx. 1 mm leaving the needle visible as a shadow through the skin.
  • the fibre (still wet) is placed inside the needle and the needle is removed. Typically no bleeding is observed at the insertion site after the insertion procedure is completed.
  • the reading device When the fibre is in place the reading device is placed directly above the fibre and the measurements can begin.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Optics & Photonics (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Measuring Fluid Pressure (AREA)

Abstract

Cette invention a pour objet un capteur de détection ou de mesure d'analyte d'hydrates de carbone (de type glucose) sous forme de fluide comportant des composants d'un dosage par liaison compétitive dont l'affichage est un signal optique détectable ou mesurable (du type dosage FRET) retenu par une substance qui permet la diffusion de l'analyte mais non la diffusion des composants de dosage, les composants de dosage contenant une lectine animale et un analogue d'analyte capable de concurrencer l'analyte pour se lier à la lectine.
PCT/EP2005/013114 2004-12-07 2005-12-07 Capteur de detection d'hydrates de carbone WO2006061207A1 (fr)

Priority Applications (22)

Application Number Priority Date Filing Date Title
DK05817676.9T DK1828773T3 (da) 2004-12-07 2005-12-07 Sensor til påvisning af carbohydrat
AT05817676T ATE514084T1 (de) 2004-12-07 2005-12-07 Sensor zum nachweis von kohlenhydrat
EP05817676A EP1828773B1 (fr) 2004-12-07 2005-12-07 Capteur de detection d'hydrates de carbone
US11/791,924 US8700113B2 (en) 2004-12-07 2005-12-07 Sensor for detection of carbohydrate
CN200580046306.XA CN101107524B (zh) 2004-12-07 2005-12-07 检测糖类的传感器
JP2007543804A JP4809363B2 (ja) 2004-12-07 2005-12-07 糖質検出用センサー
AU2005313564A AU2005313564B2 (en) 2004-12-07 2005-12-07 Sensor for detection of carbohydrate
CA2589547A CA2589547C (fr) 2004-12-07 2005-12-07 Capteur de detection d'hydrates de carbone
GBGB0611773.3A GB0611773D0 (en) 2005-12-07 2006-06-14 Flexible carbohydrate-bearing polymer
CA2631807A CA2631807C (fr) 2005-12-07 2006-12-06 Polymere flexible portant des hydrates de carbone
DK06829339.8T DK1955072T3 (da) 2005-12-07 2006-12-06 Fleksibel carbohydratbærende polymer
US12/085,961 US8691517B2 (en) 2004-12-07 2006-12-06 Flexible carbohydrate-bearing polymer
NZ568486A NZ568486A (en) 2005-12-07 2006-12-06 Flexible carbohydrate-bearing polymer and Sensor comprising the same useful in the detection or measurement of a carbohydrate in a fluid
PCT/EP2006/011708 WO2007065653A1 (fr) 2005-12-07 2006-12-06 Polymère flexible portant des hydrates de carbone
AU2006322176A AU2006322176B2 (en) 2005-12-07 2006-12-06 Flexible carbohydrate-bearing polymer
JP2008543719A JP5033810B2 (ja) 2005-12-07 2006-12-06 柔軟性糖質を有するポリマーを有するセンサーおよびそのためのポリマーの合成方法
EP06829339A EP1955072B1 (fr) 2005-12-07 2006-12-06 Polymère flexible portant des hydrates de carbone
CN200680045824.4A CN101365947B (zh) 2005-12-07 2006-12-06 含糖柔性聚合物
AT06829339T ATE514085T1 (de) 2005-12-07 2006-12-06 Flexibles kohlenhydrat tragendes polymer
NO20073392A NO342192B1 (no) 2004-12-07 2007-07-02 Sensor for påvisning av karbohydrater
NO20082858A NO20082858L (no) 2005-12-07 2008-06-23 Fleksibel karbohydratbaerende polymer
US14/178,756 US20140200336A1 (en) 2004-12-07 2014-02-12 Flexible carbohydrate-bearing polymer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0426823.1A GB0426823D0 (en) 2004-12-07 2004-12-07 Sensor for detection of glucose
GB0426823.1 2004-12-07

Publications (1)

Publication Number Publication Date
WO2006061207A1 true WO2006061207A1 (fr) 2006-06-15

Family

ID=34073311

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/013114 WO2006061207A1 (fr) 2004-12-07 2005-12-07 Capteur de detection d'hydrates de carbone

Country Status (11)

Country Link
US (3) US8700113B2 (fr)
EP (1) EP1828773B1 (fr)
JP (1) JP4809363B2 (fr)
CN (1) CN101107524B (fr)
AT (1) ATE514084T1 (fr)
AU (1) AU2005313564B2 (fr)
CA (1) CA2589547C (fr)
DK (1) DK1828773T3 (fr)
GB (1) GB0426823D0 (fr)
NO (1) NO342192B1 (fr)
WO (1) WO2006061207A1 (fr)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009073625A1 (fr) * 2007-11-29 2009-06-11 Receptors Llc Capteurs utilisant des récepteurs artificiels combinatoires
US7884052B2 (en) 2004-09-03 2011-02-08 Receptors Llc Combinatorial artificial receptors including tether building blocks on scaffolds
US7960311B2 (en) 2002-09-16 2011-06-14 Receptors Llc Methods employing combinatorial artificial receptors
US7964535B2 (en) 2002-03-01 2011-06-21 Receptors Llc Arrays and artificial receptors
US7985715B2 (en) 2004-09-11 2011-07-26 Receptors Llc Combinatorial artificial receptors including peptide building blocks
WO2012080258A1 (fr) * 2010-12-17 2012-06-21 Eyesense Ag Utilisation d'hydrogels pour des biocapteurs à sensibilité accrue
WO2013036492A1 (fr) * 2011-09-06 2013-03-14 Medtronic Minimed, Inc. Glucose sensor
WO2013066930A1 (fr) 2011-11-01 2013-05-10 Medtronic Minimed, Inc. Procédés et matériels pour moduler le temps de démarrage et l'élimination d'air dans des capteurs à sec
WO2013074668A1 (fr) 2011-11-17 2013-05-23 Medtronic Minimed, Inc. Formulations aqueuses de protection vis-à-vis d'un rayonnement et procédé de réalisation et d'utilisation de celles-ci
US8691517B2 (en) 2004-12-07 2014-04-08 Medtronic Minimed, Inc. Flexible carbohydrate-bearing polymer
WO2015061593A1 (fr) 2013-10-25 2015-04-30 Medtronic Minimed, Inc. Capteur à interface optique
WO2016196662A1 (fr) 2015-06-02 2016-12-08 Medtronic Minimed, Inc. Agents de protection des protéines contre une exposition à un faisceau électronique en chimie par détection optique
WO2018169408A1 (fr) * 2017-03-15 2018-09-20 Lifecare As Composition de fluide, procédé de préparation de la composition et son utilisation

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070134685A1 (en) * 2005-09-06 2007-06-14 Invitrogen Corporation Control of chemical modification
US7704704B2 (en) * 2005-09-28 2010-04-27 The Texas A&M University System Implantable system for glucose monitoring using fluorescence quenching
EP1955072B1 (fr) * 2005-12-07 2011-06-22 PreciSense A/S Polymère flexible portant des hydrates de carbone
US7751907B2 (en) 2007-05-24 2010-07-06 Smiths Medical Asd, Inc. Expert system for insulin pump therapy
US8926561B2 (en) 2009-07-30 2015-01-06 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
US10010272B2 (en) 2010-05-27 2018-07-03 Profusa, Inc. Tissue-integrating electronic apparatus
CN103260501B (zh) 2010-10-06 2015-09-02 普罗弗萨股份有限公司 组织整合性传感器
AU2011344290B2 (en) * 2010-12-17 2016-02-25 Eyesense Ag Competitive biosensor having elevated sensitivity
US20140235790A1 (en) * 2011-06-10 2014-08-21 University Of Washington Through Its Center For Commercialization Carbohydrate-based compositions and methods for targeted drug delivery
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
JP6412883B2 (ja) * 2013-01-22 2018-10-24 ベクトン・ディキンソン・アンド・カンパニーＢｅｃｔｏｎ， Ｄｉｃｋｉｎｓｏｎ Ａｎｄ Ｃｏｍｐａｎｙ 蛍光検出のための小型化した光カプラ
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
US20140350370A1 (en) * 2013-04-08 2014-11-27 The Texas A&M University System Glucose sensing assay
JP5889487B2 (ja) * 2013-06-04 2016-03-22 パナソニック株式会社 センサーチップ、検出方法および検出装置
WO2018119400A1 (fr) 2016-12-22 2018-06-28 Profusa, Inc. Système et capteur luminescent à canal unique et procédé de détermination de valeur d'analyte
US10792378B2 (en) * 2017-04-28 2020-10-06 Medtronics Minimed, Inc. Using a blue-shifted reference dye in an optical glucose assay
US10543288B2 (en) 2017-04-28 2020-01-28 Medtronic Minimed, Inc. Modified-dextrans for use in optical glucose assays
US11275050B2 (en) * 2017-12-05 2022-03-15 Femtodx, Inc. Semiconductor-based biosensor and detection methods
US20210087614A1 (en) * 2018-02-28 2021-03-25 The Regents Of The University Of California Electrochemical biosensor array devices, systems, and methods for point-of-care detection

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342789A (en) * 1989-12-14 1994-08-30 Sensor Technologies, Inc. Method and device for detecting and quantifying glucose in body fluids
WO1998055869A1 (fr) * 1997-06-04 1998-12-10 Sensor Technologies, Inc. Procede et dispositif de detection ou d'evaluation de composes contenant des glucides
WO2000016099A1 (fr) * 1998-09-11 2000-03-23 Sensor Technologies, Inc. Ligands de liaison d'hydrate de carbone a valence reduite recombinants
US20030216300A1 (en) 2002-05-20 2003-11-20 Cantor Jerome Owen Lectins as anti-fibrotic agents
US20040265898A1 (en) 1999-08-12 2004-12-30 Agensys, Inc. C-type lectin transmembrane antigen expressed in human prostate cancer and uses thereof

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4679562A (en) * 1983-02-16 1987-07-14 Cardiac Pacemakers, Inc. Glucose sensor
DK570485D0 (da) 1985-12-10 1985-12-10 Novo Industri As Humant conglutinin
US4952656A (en) * 1986-10-01 1990-08-28 Air Products And Chemicals, Inc. Manufacture of high molecular weight poly(vinylamines)
US5431160A (en) * 1989-07-19 1995-07-11 University Of New Mexico Miniature implantable refillable glucose sensor and material therefor
US5194393A (en) * 1989-11-21 1993-03-16 Bayar Aktiengesellschaft Optical biosensor and method of use
US5474915A (en) * 1990-05-08 1995-12-12 University Of Iowa Research Foundation Method of making poly(sugar acrylates) using hydrolytic enzymes
CA2053449A1 (fr) * 1990-10-16 1992-04-17 Henry K. Hui Microdetecteur de ph a fibre optique et sa methode de fabrication
DK0594772T3 (fr) 1991-07-04 1997-02-24 Immunodex K S
US5246867A (en) 1992-01-17 1993-09-21 University Of Maryland At Baltimore Determination and quantification of saccharides by luminescence lifetimes and energy transfer
US6256522B1 (en) * 1992-11-23 2001-07-03 University Of Pittsburgh Of The Commonwealth System Of Higher Education Sensors for continuous monitoring of biochemicals and related method
US5587442A (en) * 1994-12-23 1996-12-24 Kiessling; Laura L. Polyglycomers
AU717207B2 (en) * 1995-08-17 2000-03-23 Fuso Pharmaceutical Industries, Ltd. Recombinant conglutinin and producing method thereof
US6002954A (en) * 1995-11-22 1999-12-14 The Regents Of The University Of California Detection of biological molecules using boronate-based chemical amplification and optical sensors
ATE278801T1 (de) 1995-11-22 2004-10-15 Medtronic Minimed Inc Detektion von biologischen molekülen unter verwendung von chemischer amplifikation und optischem sensor
US5980948A (en) 1996-08-16 1999-11-09 Osteotech, Inc. Polyetherester copolymers as drug delivery matrices
WO1998049306A1 (fr) * 1997-04-29 1998-11-05 Incyte Pharmaceuticals, Inc. Lectine humaine de type c
US6146849A (en) * 1998-06-04 2000-11-14 University Of Georgia Research Foundation Inc. Lectins and coding sequences
DE69839054T2 (de) * 1997-09-03 2009-01-15 The Regents Of The University Of California, Oakland Biomimetrische materialien vom hydrogel-typ
AU757642B2 (en) * 1998-07-03 2003-02-27 Medtronic Minimed, Inc. Optical sensor for in situ measurement of analytes
GB9814506D0 (en) * 1998-07-03 1998-09-02 Stanley Christopher J Optical sensor for insitu measurement of analytes
USRE38525E1 (en) * 1998-07-03 2004-06-08 Torsana Diabetes Diagnostics A/S Optical sensor for in situ measurement of analytes
US6485703B1 (en) * 1998-07-31 2002-11-26 The Texas A&M University System Compositions and methods for analyte detection
ATE236669T1 (de) * 1998-11-30 2003-04-15 Isotis Nv Kunsthaut
US6271315B1 (en) * 1999-06-17 2001-08-07 Wisconsin Alumni Research Foundation Methods for making multivalent arrays
US20030125262A1 (en) * 2000-03-21 2003-07-03 Wisconsin Alumni Research Foundation Methods and reagents for regulation of cellular responses in biological systems
US20040248801A1 (en) * 2000-03-21 2004-12-09 Kiessling Laura L. Methods and reagents for regulation of cellular responses in biological systems
GB0025147D0 (en) 2000-10-13 2000-11-29 Torsana Diabetes Diagnostics A Optical sensor for in situ measurement of analytes
US6627177B2 (en) 2000-12-05 2003-09-30 The Regents Of The University Of California Polyhydroxyl-substituted organic molecule sensing optical in vivo method utilizing a boronic acid adduct and the device thereof
AU2002251944A1 (en) * 2001-02-15 2002-09-04 Medtronic Minimed, Inc. Polymers functionalized with fluorescent boronate motifs
GB0116853D0 (en) 2001-07-10 2001-09-05 Torsana Diabetes Diagnostics A Optical sensor containing particles for in SITU measurement of analytes
US7045361B2 (en) * 2001-09-12 2006-05-16 Medtronic Minimed, Inc. Analyte sensing via acridine-based boronate biosensors
AU2002340119A1 (en) 2001-10-09 2003-04-22 Immunex Corporation Mammalian c-type lectins
GB0204640D0 (en) * 2002-02-27 2002-04-10 Torsana Diabetes Diagnostics A Injection apparatus
US7297548B2 (en) * 2003-03-28 2007-11-20 Terumo Kabushiki Kaisha Solid-phase saccharide sensing compounds
JP2005036254A (ja) * 2003-07-16 2005-02-10 Mitsubishi Alum Co Ltd フィン材用ノンクロム皮膜型防食処理剤及びフィン材
GB0329161D0 (en) 2003-12-16 2004-01-21 Precisense As Reagant for detecting an analyte
GB0329849D0 (en) * 2003-12-23 2004-01-28 Precisense As Fluorometers
GB0411162D0 (en) 2004-05-19 2004-06-23 Precisense As Optical sensor for in vivo detection of analyte
GB0416732D0 (en) * 2004-07-27 2004-09-01 Precisense As A method and apparatus for measuring the phase shift induced in a light signal by a sample
US8617819B2 (en) 2004-09-17 2013-12-31 Massachusetts Institute Of Technology Polymers for analyte detection
GB0426822D0 (en) 2004-12-07 2005-01-12 Precisense As Sensor for detection of glucose
GB0426823D0 (en) 2004-12-07 2005-01-12 Precisense As Sensor for detection of glucose

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342789A (en) * 1989-12-14 1994-08-30 Sensor Technologies, Inc. Method and device for detecting and quantifying glucose in body fluids
WO1998055869A1 (fr) * 1997-06-04 1998-12-10 Sensor Technologies, Inc. Procede et dispositif de detection ou d'evaluation de composes contenant des glucides
US6232130B1 (en) 1997-06-04 2001-05-15 Sensor Technologies, Inc. Method for detecting or quantifying carbohydrate containing compounds
WO2000016099A1 (fr) * 1998-09-11 2000-03-23 Sensor Technologies, Inc. Ligands de liaison d'hydrate de carbone a valence reduite recombinants
US20040265898A1 (en) 1999-08-12 2004-12-30 Agensys, Inc. C-type lectin transmembrane antigen expressed in human prostate cancer and uses thereof
US20030216300A1 (en) 2002-05-20 2003-11-20 Cantor Jerome Owen Lectins as anti-fibrotic agents

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BALLERSTADT R ET AL: "COMPETITIVE-BINDING ASSAY METHOD BASED ON FLUORESCENCE QUENCHING OFLIGANDS HELD IN CLOSE PROXIMITY BY A MULTIVALENT RECEPTOR", ANALYTICA CHIMICA ACTA, ELSEVIER, AMSTERDAM, NL, vol. 345, no. 1-3, 1997, pages 203 - 212, XP000901095, ISSN: 0003-2670 *
EUR J BIOCHEM, vol. 267, pages 1665 - 71
EUR J IMMUNOL, vol. 25, pages 2433 - 7
EUR J IMMUNOL, vol. 34, pages 210 - 20
IMMUNOL LETT, vol. 67, pages 109 - 12
MOL BIOL CELL, vol. 7, pages 483 - 93
PARFUEMERIE UND KOSMETIK, vol. 74, pages 164 - 80
RYAN J. RUSSELL ET AL.: "A Potentially Implantable Fluorescent Glucose Sensor Based on Molecular Recognition in Poly(ethylene glycol) Hydrogels", AMERICAN INSTITUTE OF CHEMICAL ENGINEERS

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7964535B2 (en) 2002-03-01 2011-06-21 Receptors Llc Arrays and artificial receptors
US7960311B2 (en) 2002-09-16 2011-06-14 Receptors Llc Methods employing combinatorial artificial receptors
US7884052B2 (en) 2004-09-03 2011-02-08 Receptors Llc Combinatorial artificial receptors including tether building blocks on scaffolds
US7985715B2 (en) 2004-09-11 2011-07-26 Receptors Llc Combinatorial artificial receptors including peptide building blocks
US8691517B2 (en) 2004-12-07 2014-04-08 Medtronic Minimed, Inc. Flexible carbohydrate-bearing polymer
CN101952726A (zh) * 2007-11-29 2011-01-19 受体有限责任公司 使用组合的人工受体的传感器
WO2009073625A1 (fr) * 2007-11-29 2009-06-11 Receptors Llc Capteurs utilisant des récepteurs artificiels combinatoires
WO2012080258A1 (fr) * 2010-12-17 2012-06-21 Eyesense Ag Utilisation d'hydrogels pour des biocapteurs à sensibilité accrue
US9244064B2 (en) 2010-12-17 2016-01-26 Eyesense Ag Use of hydrogels for biosensors having elevated sensitivity
US9642568B2 (en) 2011-09-06 2017-05-09 Medtronic Minimed, Inc. Orthogonally redundant sensor systems and methods
WO2013036492A1 (fr) * 2011-09-06 2013-03-14 Medtronic Minimed, Inc. Glucose sensor
CN103917858A (zh) * 2011-09-06 2014-07-09 美敦力米尼梅德有限公司 葡萄糖传感器
US11931145B2 (en) 2011-09-06 2024-03-19 Medtronic Minimed, Inc. Orthogonally redundant sensor systems and methods
US11229384B2 (en) 2011-09-06 2022-01-25 Medtronic Minimed, Inc. Orthogonally redundant sensor systems and methods
CN103917858B (zh) * 2011-09-06 2016-05-04 美敦力米尼梅德有限公司 葡萄糖传感器
US10194845B2 (en) 2011-09-06 2019-02-05 Medtronic Minimed, Inc. Orthogonally redundant sensor systems and methods
WO2013066930A1 (fr) 2011-11-01 2013-05-10 Medtronic Minimed, Inc. Procédés et matériels pour moduler le temps de démarrage et l'élimination d'air dans des capteurs à sec
US9989522B2 (en) 2011-11-01 2018-06-05 Medtronic Minimed, Inc. Methods and materials for modulating start-up time and air removal in dry sensors
US9421287B2 (en) 2011-11-17 2016-08-23 Medtronic Minimed, Inc. Methods for making an aqueous radiation protecting formulation
WO2013074668A1 (fr) 2011-11-17 2013-05-23 Medtronic Minimed, Inc. Formulations aqueuses de protection vis-à-vis d'un rayonnement et procédé de réalisation et d'utilisation de celles-ci
US8999720B2 (en) 2011-11-17 2015-04-07 Medtronic Minimed, Inc. Aqueous radiation protecting formulations and methods for making and using them
WO2015061593A1 (fr) 2013-10-25 2015-04-30 Medtronic Minimed, Inc. Capteur à interface optique
WO2016196662A1 (fr) 2015-06-02 2016-12-08 Medtronic Minimed, Inc. Agents de protection des protéines contre une exposition à un faisceau électronique en chimie par détection optique
WO2018169408A1 (fr) * 2017-03-15 2018-09-20 Lifecare As Composition de fluide, procédé de préparation de la composition et son utilisation

Also Published As

Publication number Publication date
CN101107524A (zh) 2008-01-16
CN101107524B (zh) 2011-12-21
ATE514084T1 (de) 2011-07-15
NO342192B1 (no) 2018-04-16
GB0426823D0 (en) 2005-01-12
EP1828773A1 (fr) 2007-09-05
JP2008523357A (ja) 2008-07-03
AU2005313564B2 (en) 2011-07-14
US20090187084A1 (en) 2009-07-23
DK1828773T3 (da) 2011-10-10
US20080188723A1 (en) 2008-08-07
US8691517B2 (en) 2014-04-08
CA2589547A1 (fr) 2006-06-15
NO20073392L (no) 2007-09-05
AU2005313564A1 (en) 2006-06-15
EP1828773B1 (fr) 2011-06-22
US8700113B2 (en) 2014-04-15
JP4809363B2 (ja) 2011-11-09
CA2589547C (fr) 2014-02-11
US20140200336A1 (en) 2014-07-17

Similar Documents

Publication Publication Date Title
EP1828773B1 (fr) Capteur de detection d'hydrates de carbone
EP1831691B1 (fr) Capteur de detection d'hydrates de carbone
EP1955072B1 (fr) Polymère flexible portant des hydrates de carbone
US20050239155A1 (en) Entrapped binding protein as biosensors
WO2006096746A1 (fr) Proteine de liaison piegee en tant que biocapteurs
US20040234962A1 (en) Multicoated or multilayer entrapment matrix for protein biosensor
US8389290B2 (en) Biosensor device for sensing amphipathic analytes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2589547

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007543804

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 555992

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 4931/DELNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2005313564

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005817676

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200580046306.X

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2005313564

Country of ref document: AU

Date of ref document: 20051207

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005313564

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005817676

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11791924

Country of ref document: US